je.st
news
Tag: update merck
Merck Provides Regulatory Update on Investigational Medicine Sugammadex Injection
2015-03-13 21:02:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, said it was informed today that the U.S. Food and Drug Administration (FDA) has cancelled the meeting of the Anesthetic and Analgesic Drug Products Advisory Committee scheduled for March 18, 2015. The committee had planned to discuss the resubmission of the New Drug Application (NDA) for sugammadex injection, Mercks investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or vecuronium. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: update
medicine
regulatory
injection
Merck Provides Update on Strategic Actions to Transform the Company and Build a Platform for Sustained Future Growth at the 33rd Annual J.P. Morgan Healthcare Conference
2015-01-12 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KEYTRUDA, First FDA-Approved Anti-PD-1 Therapy, Filed and Launched Within Five Months Company Expects to Submit sBLA for KEYTRUDA in Mid-Year 2015 for Advanced Non-Small Cell Lung Cancer NDA Submission for Hepatitis C Combination Regimen, Grazoprevir/Elbasvir (MK-5172/MK-8742), Planned for First Half of 2015 Seven New Products were Approved in 2014 Company Announced Acquisition of Cubist, Acquired Idenix and Divested its Consumer Care Business Targeted Cost Savings are on Track to be Realized by the End of 2015 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today will report on the ongoing execution of its multi-year, strategic initiative to sharpen its commercial and research and development (R&D) focus, redesign its operating model and reduce its cost base. In October 2013, Merck launched its global initiative to transform the company into a more competitive and innovative company and to build a platform for sustained future growth. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Steven Cragle, 908-740-1801orInvestors:Justin Holko, 908-740-1879Joe Romanelli, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
company
future
update
Merck Animal Health Provides Update on Zilmax Five-Step Plan, Announces Next Steps
2014-11-05 14:30:00| Merck.com - Corporate News
Dateline City: SUMMIT, N.J. Extensive review and analysis of research data completed Final stage to focus on planned in-field use studies Best Management Practices and Certification Program adopted FDA approval of updates to Zilmax label, including new feed delivery method SUMMIT, N.J.--(BUSINESS WIRE)--Merck Animal Health (known outside the United States and Canada as MSD Animal Health) is pleased to announce significant progress in the implementation of its Zilmax Five-Step Plan. With insights from the companys advisory board, an extensive assessment and analysis of existing, as well as new product data, was conducted. Additionally, Merck Animal Health obtained the input of industry experts, business partners and customers about the product and its use. Language: English Contact: Merck Animal HealthMedia:Pam Eisele, 267-305-3558Kelly Goss, 913-422-6846orInvestor:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: health
plan
update
steps
Merck Animal Health Provides Update on Zilmax Five-Step Plan, Announces Next Steps
2014-11-04 06:00:00| Beef
Merck Animal Health is announcing significant progress in the implementation of its Zilmax Five-Step Plan. With insights from the company’s advisory board, an extensive assessment and analysis of existing, as well as new product data, was conducted. Additionally, Merck Animal Health obtained the input of industry experts, business partners and customers about the product and its use. In a release, Merck Animal Health provided an update on the Zilmax Five-Step Plan, and announced the following steps: read more
Tags: health
plan
update
steps
UPDATE 1-Bristol, Merck, Roche immune therapies are cancer meeting focus
2014-05-15 03:35:01| Biotech - Topix.net
When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck & Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight.
Tags: update
focus
meeting
cancer